In vitro Inhibition of CYP1A2 by Model Inhibitors, Anti-Inflammatory Analgesics and Female Sex Steroids: Predictability of in vivo Interactions
Marjo J. Karjalainen,
Pertti J. Neuvonen,
Janne T. Backman,
Marjo J. Karjalainen
Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
Search for more papers by this authorPertti J. Neuvonen
Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
Search for more papers by this authorJanne T. Backman
Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
Search for more papers by this authorMarjo J. Karjalainen,
Pertti J. Neuvonen,
Janne T. Backman,
Marjo J. Karjalainen
Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
Search for more papers by this authorPertti J. Neuvonen
Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
Search for more papers by this authorJanne T. Backman
Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
Search for more papers by this authorAuthor for correspondence: Janne T. Backman, Department of Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4, FI-00290 Helsinki, Finland (fax +358 9 471 74039, e-mail: [email protected]).
Abstract
Abstract: The cytochrome P450 enzyme CYP1A2 is crucial for the metabolism of many drugs, for example, tizanidine. As the effects of several non-steroidal anti-inflammatory drugs (NSAID) and female sex steroids on CYP1A2 activity in vitro are unknown, their effects on phenacetin O-deethylation were studied and compared with the effects of model inhibitors in human liver microsomes, followed by prediction of their interaction potential with tizanidine in vivo. In vitro, fluvoxamine, tolfenamic acid, mefenamic acid and rofecoxib potently inhibited CYP1A2 [the 50% inhibitory concentration (IC50) < 10 µM]. Ethinyloestradiol, celecoxib, desogestrel and zolmitriptan were moderate (IC50 20–200 µM), and etodolac, ciprofloxacin, etoricoxib and gestodene weak inhibitors of CYP1A2 (IC50 > 200 µM). At 100 µM, the other tested NSAIDs and steroids inhibited CYP1A2 less than 35%. Pre-incubation increased the inhibitory effects of rofecoxib, progesterone and desogestrel. Using the free portal plasma inhibitor concentration and the competitive inhibition model, the effect of fluvoxamine and the lack of effects of tolfenamic acid and celecoxib on tizanidine pharmacokinetics in human beings were well predicted. However, the effects of ciprofloxacin, rofecoxib and oral contraceptives were greatly underestimated even when the predictions were based on their total portal plasma concentration. Besides rofecoxib, and possibly mefenamic acid, other NSAIDs were predicted not to significantly inhibit CYP1A2 in human beings. The type of enzyme inhibition, particularly metabolism-dependent inhibition, free inhibitor concentration and accumulation of the inhibitor into the hepatocytes should be considered in extrapolations of in vitro results to human beings.
References
- 1 Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 2005; 97: 125–34.
- 2 Rasmussen BB, Brix TH, Kyvik KO, Brøsen K. The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 2002; 12: 473–8.
- 3 Korhonen LE, Rahnasto M, Mahonen NJ, Wittekindt C, Poso A, Juvonen RO et al . Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem 2005; 48: 3808–15.
- 4 Berthou F, Flinois JP, Ratanasavanh D, Beaune P, Riche C, Guillouzo A. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos 1991; 19: 561–7.
- 5 Zhang ZY, Kaminsky LS. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol 1995; 50: 205–11.
- 6 Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol 2004; 57: 349–53.
- 7 Wild MJ, McKillop D, Butters CJ. Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan. Xenobiotica 1999; 29: 847–57.
- 8 Distlerath LM, Reilly PE, Martin MV, Davis GG, Wilkinson GR, Guengerich FP. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1985; 260: 9057–67.
- 9 Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U et al . Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38: 471–3.
- 10 Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211–4.
- 11 Fuhr U, Anders EM, Mahr G, Sorgel F, Staib AH. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother 1992; 36: 942–8.
- 12 Kunze KL, Trager WF. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 1993; 6: 649–56.
- 13 Granfors MT, Backman JT, Neuvonen M, Ahonen J, Neuvonen PJ. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther 2004; 75: 331–41.
- 14 Backman JT, Karjalainen MJ, Neuvonen M, Laitila J, Neuvonen PJ. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol 2006; 62: 345–57.
- 15 Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 2004; 76: 598–606.
- 16 Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther 2005; 78: 400–11.
- 17 Karjalainen MJ, Neuvonen PJ, Backman JT. Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions. Drug Metab Dispos 2006; 34: 2091–6.
- 18 Karjalainen MJ, Neuvonen PJ, Backman JT. Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. Eur J Clin Pharmacol 2007; 63: 829–36.
- 19 Bachmann KA. Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise. Curr Drug Metab 2006; 7: 1–14.
- 20 Yao C, Levy RH. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J Pharm Sci 2002; 91: 1923–35.
- 21
Ito K,
Chiba K,
Horikawa M,
Ishigami M,
Mizuno N,
Aoki J
et al
. Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?
AAPS Pharm Sci
2002; 4: article
25.
10.1208/ps040425 Google Scholar
- 22 Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 2004; 57: 473–86.
- 23 Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug–drug interactions. J Pharmacol Exp Ther 2006; 316: 336–48.
- 24 Brown HS, Galetin A, Hallifax D, Houston JB. Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 2006; 45: 1035–50.
- 25 Pelkonen O, Turpeinen M, Uusitalo J, Rautio A, Raunio H. Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic Clin Pharmacol Toxicol 2005; 96: 167–75.
- 26 Brown HS, Ito K, Galetin A, Houston JB. Prediction of in vivo drug–drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 2005; 60: 508–18.
- 27 Tornheim K. Kinetic applications using high substrate and competitive inhibitor concentrations to determine Ki or Km. Anal Biochem 1994; 221: 53–6.
- 28 Madan A, Usuki E, Burton L, Ogilvie B, Parkinson A. In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs. In: AD Rodrigues (ed.). Drug–Drug Interactions. Merkel Dekker Inc., West Point, NY, 2002; 217–94.
- 29 Karjalainen MJ, Neuvonen PJ, Backman JT. Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. Eur J Clin Pharmacol 2008; 64: 511–9.
- 30 Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S et al . The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31: 815–32.
- 31 Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC et al . Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 1993; 265: 401–7.
- 32 Fuhr U, Wolff T, Harder S, Schymanski P, Staib AH. Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metab Dispos 1990; 18: 1005–10.
- 33 Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51: 73–8.
- 34 Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I et al . Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin Pharmacol Ther 2001; 70: 415–24.
- 35 Harder S, Fuhr U, Staib AH, Wolff T. Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations. Am J Med 1989; 87: 89S–91S.
- 36 Grime K, Riley RJ. The impact of in vitro binding on in vitro–in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr Drug Metab 2006; 7: 251–64.
- 37 Regmi NL, Abd El-Aty AM, Kuroha M, Nakamura M, Shimoda M. Inhibitory effect of several fluoroquinolones on hepatic microsomal cytochrome P-450 1A activities in dogs. J Vet Pharmacol Ther 2005; 28: 553–7.
- 38 Fuhr U, Strobl G, Manaut F, Anders EM, Sorgel F, Lopez-de-Brinas E et al . Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol Pharmacol 1993; 43: 191–9.
- 39 Roberts RK, Grice J, McGuffie C, Heilbronn L. Oral contraceptive steroids impair the elimination of theophylline. J Lab Clin Med 1983; 101: 821–5.
- 40 Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 1985; 28: 425–8.
- 41 Helton ED, Goldzieher JW. Metabolism of ethynyl estrogens. J Toxicol Environ Health 1977; 3: 231–41.
- 42 Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z et al . Pharmacokinetic drug interactions involving 17alpha- ethinylestradiol: a new look at an old drug. Clin Pharmacokinet 2007; 46: 133–57.
- 43 Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J et al . Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 2006; 34: 191–7.
- 44 Gentile DM, Verhoeven CH, Shimada T, Back DJ. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther 1998; 287: 975–82.
- 45 Pentikäinen PJ, Neuvonen PJ, Backman C. Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent. Eur J Clin Pharmacol 1981; 19: 359–65.
- 46 Dollery C. Therapeutic Drugs, 2nd edn. Churchill Livingstone, Edinburgh, UK, 1999.
- 47 FDA Celebrex (Celecoxib) Capsules Application No.: 21-156 & 20998/S007 Clinical Pharmacology and Biopharmaceutics reviews section. 1999. URL: http://www.fda.gov/CDER/foi/nda/99/21156-S007_Celebrex.htm
- 48 Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 2003; 74: 130–7.
- 49 EMEA Celecoxib BILAG I PRODUKTRESUME. 2006. URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/onsenal/H-466-PI-da.pdf
- 50 Kassahun K, McIntosh IS, Shou M, Walsh DJ, Rodeheffer C, Slaughter DE et al . Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos 2001; 29: 813–20.
- 51 Schwartz JI, Agrawal NG, Hartford AH, Cote J, Hunt TL, Verbesselt R et al . The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin. J Clin Pharmacol 2007; 47: 620–7.
- 52 Wise R, Andrews JM, Edwards LJ. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother 1983; 23: 559–64.
- 53 Neuvonen PJ, Kivistö KT. Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids. Eur J Clin Pharmacol 1988; 35: 495–501.
- 54 Merck & Co. Inc. VIOXX (rofecoxib tablets and oral suspension). 2002. URL: http://www.merck.com/product/usa/pi_circulars/v/vioxx/vioxx_pi.pdf
- 55 Agrawal NG, Porras AG, Matthews CZ, Rose MJ, Woolf EJ, Musser BJ et al . Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol 2003; 43: 268–76.
- 56 Agrawal NG, Matthews CZ, Mazenko RS, Kline WF, Woolf EJ, Porras AG et al . Pharmacokinetics of etoricoxib in patients with renal impairment. J Clin Pharmacol 2004; 44: 48–58.
- 57
Dixon R,
Warrander A.
The clinical pharmacokinetics of zolmitriptan.
Cephalalgia
1997; 18: 15–20.
10.1177/0333102497017S1803 Google Scholar
- 58 Van Den Heuvel MW, Van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005; 72: 168–74.
- 59 Kuhnz W, Pfeffer M, Al-Yacoub G. Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum. J Steroid Biochem 1990; 35: 313–8.
- 60 Stanczyk FZ. Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism. Contraception 1997; 55: 273–82.
- 61 Kuhl H, Jung-Hoffmann C, Heidt F. Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 75 micrograms gestodene. Contraception 1988; 38: 477–86.
Citing Literature
